Document Detail


Recent developments in acute coronary syndromes.
MedLine Citation:
PMID:  18335668     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary artery disease is the leading cause of death in the UK with a high clinical, social and economic burden. The management of acute coronary syndromes is rapidly evolving and clinicians are constantly challenged with incorporating new clinical pathways and guidelines into their practices. It is important for clinicians to have a sound working knowledge of acute coronary syndromes, and be updated on the emerging evidence to guide therapy and improve outcomes in these patients.
Authors:
M Bilal Iqbal; Mark A Westwood; R Howard Swanton
Related Documents :
5572638 - Coronary circulation in acute myocardial infarction.
17520358 - Transcatheter cryoablation with 3-d mapping of an atrial ectopic tachycardia in a pedia...
20144388 - An overview of glycemic control in the coronary care unit with recommendations for clin...
15900998 - Cardiac complications of radiation therapy.
12724648 - Temporal changes and histologic relation of postsystolic thickening in an animal model ...
472308 - Cinefluoroscopy in evaluating left ventricular contractility and aneurysms.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical medicine (London, England)     Volume:  8     ISSN:  1470-2118     ISO Abbreviation:  Clin Med     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-03-13     Completed Date:  2008-05-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101092853     Medline TA:  Clin Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  42-8     Citation Subset:  IM    
Affiliation:
The Heart Hospital, University College London Hospitals NHS Trust. biqbal@excite.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary* / methods
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Anticoagulants / therapeutic use
Antithrombins / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Hirudins
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Myocardial Infarction / drug therapy,  mortality,  prevention & control,  therapy*
Peptide Fragments / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Polysaccharides / therapeutic use
Recombinant Proteins / therapeutic use
Thrombolytic Therapy*
Ticlopidine / analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticoagulants; 0/Antithrombins; 0/Heparin, Low-Molecular-Weight; 0/Hirudins; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Peptide Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Polysaccharides; 0/Recombinant Proteins; 0/fondaparinux; 128270-60-0/bivalirudin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Self-poisoning: current trends and practice in a U.K. teaching hospital.
Next Document:  Ethical planning for an influenza pandemic.